Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo

Yiqing Zhao1,2, Xuan Zhao1,2, Vanessa Chen1,3, Ying Feng4, Lan Wang3, Colleen Croniger3, Ronald A. Conlon1,2, Sanford Markowitz1,2,5,6, Eric Fearon4, Michelle Puchowicz3, Henri Brunengraber1, Yujun Hao1,2,7,8* & Zhenghe Wang1,2,8*

Cancer cells in culture rely on glutamine as an anaplerotic substrate to replenish tricarboxylic acid (TCA) cycle intermediates that have been consumed. But it is uncertain whether cancers in vivo depend on glutamine for anaplerosis. Here, following in vivo infusions of [13C5]-glutamine in mice bearing subcutaneous colon cancer xenografts, we showed substantial amounts of infused [13C5]-glutamine enters the TCA cycle in the tumors. Consistent with our prior observation that colorectal cancers (CRCs) with oncogenic mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic (PIK3CA) subunit are more dependent on glutamine than CRCs with wild type PIK3CA, labeling from glutamine to most TCA cycle intermediates was higher in PIK3CA-mutant subcutaneous xenograft tumors than in wild type PIK3CA tumors. Moreover, using orthotopic mouse colon tumors established from human CRC cells or patient-derived xenografts, we demonstrated substantial amounts of infused [13C5]-glutamine enters the TCA cycle in the tumors and tumors utilize anaplerotic glutamine to a greater extent than adjacent normal colon tissues. Similar results were seen in spontaneous colon tumors arising in genetically engineered mice. Our studies provide compelling evidence CRCs utilizes glutamine to replenish the TCA cycle in vivo, suggesting that targeting glutamine metabolism could be a therapeutic approach for CRCs, especially for PIK3CA-mutant CRCs.

It has been long recognized that cultured cancer cells can utilize glutamine as an anaplerotic substrate of the tricarboxylic acid (TCA) cycle1. Optimal operation of the TCA cycle allows the cancer cell to generate ATP and precursors for synthesis of lipids, nucleotides and other macromolecules2–5. Before entering the TCA cycle, glutamine is deamidated by glutaminases (GLSs), forming glutamate which is converted to α-ketoglutarate (α-KG), a TCA cycle intermediate3,6. A recent study found that cultured lung cancer cells use anaplerotic [13C5]-glutamine. However, when [13C5]-glutamine is infused in vivo, there was low labeling of the TCA cycle intermediates in the tumors7. These observations raise the possibility that glutamine dependency or addiction of cancers could be an artifact of cell culture, perhaps resulting from the high concentration of glutamine present in media.

We recently found that PIK3CA mutations render colorectal cancer (CRC) cells dependent on glutamine. PIK3CA, which encodes the catalytic subunit of phosphatidylinositol 3-kinase α (PI3Kα), is mutated in a wide variety of human cancers including ~30% of CRCs8. While PI3Ks convert phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3)9,10, the tumor suppressor protein PTEN catalyzes the reverse reaction11. The glutamine dependency of PIK3CA-mutant cancer cells is associated with upregulation of mitochondrial glutamate pyruvate transaminase 2 (GPT2)12, which converts glutamate to α-KG. Moreover, we demonstrated that aminoxyacetate (AOA), a pan-aminotransferase inhibitor, suppresses xenograft tumor growth of PIK3CA-mutant CRC, but not PIK3CA wild type (PIK3CA WT) CRC12. Interestingly, loss of PTEN

1Department of Genetics and Genome Sciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, 44106, USA. 2Case Comprehensive Cancer Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, 44106, USA. 3Department of Nutrition, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, 44106, USA. 4Departments of Internal Medicine, Human Genetics, and Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA. 5Department of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, 44106, USA. 6Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, 44106, USA. 7Present address: Shanghai Cancer Institute, Shanghai Jiao-Tong University School of Medicine Renji Hospital, 25/Ln 2200 Xietu Road, Shanghai, 200032, P.R. China. 8These authors jointly supervised this work: Yujun Hao and Zhenghe Wang. *email: yjhao@shsci.org; zxw22@case.edu
also make breast cancers dependent on glutamine\textsuperscript{13}. These observations indicate that the PI3K pathway plays a critical role in modulating glutamine metabolism in certain cancer types.

We previously showed that glutamine is anaplerotic in CRC cells in tissue culture\textsuperscript{12}. Here, we infused \( ^{[13]C_5} \)-glutamine in mice with subcutaneous or orthotopic xenografts, and in mice genetically engineered to develop colon cancer. We found that infused \( ^{[13]C_5} \)-glutamine labels the TCA intermediates of the tumor in vivo.

**Results**

\( ^{[13]C_5} \)-glutamine in mouse plasma plateaus at 4 hours after infusion. We first traced glutamine metabolites in multiple nude mice carrying xenograft tumors formed by isogenic HCT116 PIK3CA-WT-only CRC cells (where the mutant PIK3CA allele was inactivated) in the left flank or PIK3CA-mutant-only (with the PIK3CA WT allele inactivated) CRC cells\textsuperscript{15} in the right flank (Fig. 2A,B). Consistent with our glutamine tracing data in tissue culture cells\textsuperscript{12}, the labeling from glutamine of most of TCA cycle intermediates was higher in PIK3CA-mutant tumors than in PIK3CA-WT tumors (Fig. 2C). In contrast, the labeling from glucose of the TCA cycle intermediates was not different between PIK3CA-mutant tumors and PIK3CA-WT tumors (Fig. S1). We then compared the total labeling of each metabolite to the total labeling of glutamine. As shown in Fig. 2D, the labeling of glutamate and succinate were 60\% and 40\% of the labeling of glutamine, respectively. Also, the labeling of fumarate, malate and citrate were 30\% to 40\% of the labeling of glutamine (Fig. 2D). These data show that glutamine is a major anaplerotic substrate of the TCA in colorectal xenograft tumors.
CRCs utilize glutamine as an anaplerotic substrate of the TCA cycle in orthotopic xenograft tumor models. Next, we traced the labeling of glutamine in metabolites in orthotopic colon cancer models, which provide an organ-relevant tumor microenvironment. Although not statistically significant, the labeling of glutamine-derived metabolites was higher in tumors established from HCT116 PIK3CA-mutant only cells than in tumors established from the HCT116 PIK3CA-WT only cells (Fig. 3A). Nonetheless in the tumors, the labeling of metabolites from glutamine was greater than in the adjacent normal cecum tissues (Fig. 3B). It seems that glutamine is metabolized in a similar fashion at different locations in colon, as similar amounts of isotopic enrichments of glutamine, glutamate and the TCA intermediates were observed in cecum and colon tissues (Fig. S2). As with the subcutaneous xenograft models, glutamine substantially labeled glutamate and TCA cycle intermediates in orthotopic xenograft tumors (Fig. 3C).

A patient-derived CRC xenograft utilizes glutamine as an anaplerotic substrate of the TCA cycle in an orthotopic model. It is generally believed that patient-derived xenografts (PDXs) recapitulate the heterogeneity of human cancer better than xenografts established from cancer-derived cell lines. We thus performed [13C5]-glutamine tracing in mice bearing orthotopic tumors established from a PDX. As shown in Fig. 4A, the enrichments of M5-labeled glutamate and M4-labeled succinate, fumarate, malate, and citrate were significantly higher in the PDX tumors than in the adjacent cecum and colon tissues (Fig. S2). As with the subcutaneous xenograft models, glutamine substantially labeled glutamate and TCA cycle intermediates in orthotopic xenograft tumors (Fig. 3C).

Spontaneously arising mouse colon tumors carrying PIK3CA alterations utilize glutamine as an anaplerotic substrate of the TCA cycle. To determine how spontaneous colon tumors metabolize glutamine in immune-competent mice, we infused [13C5]-glutamine in CDX2P-CreERT2 ApoDlox/lox KrasLSL-G12D/Pik3caLSL-E545K mice, which developed multiple advanced non-invasive and invasive colon tumors in the cecum and proximal colon within two months after tamoxifen administration (Fig. 5A). Although the labeling of glutamine was similar in tumor tissues and adjacent normal colon tissues, the enrichments of M5-labeled glutamate...
and M4-labeled succinate, fumarate, malate and citrate were significantly higher in tumors than normal tissues (Fig. 5B). Furthermore, TCA cycle intermediates were labeled at 30% of the level of glutamine (Fig. 5C). Together, these data demonstrate that anaplerosis from glutamine is more intense in colon tumors than in normal colon tissues \textit{in vivo} and that a substantial fraction of TCA cycle intermediates are derived from glutamine.

**Discussion**

Our \textit{in vivo} glutamine infusion data in subcutaneous, orthotopic and genetically engineered colon tumor models clearly demonstrate that (1) a substantial fraction of glutamine in tumors enters the TCA cycle and (2) relative anaplerosis from glutamine is more intense in the tumors than in adjacent normal colon tissues. While our data demonstrate that glutamine is a major anaplerotic substrate for CRCs, Vander Heiden and colleagues have previously reported that only minimal amounts of glutamine enter the TCA cycle in spontaneous lung tumors arising from activation of a mutant Kras allele in mouse lung epithelium. In orthotopic glioblastoma models, Marin-Valencia and co-workers reported that the three glioblastoma PDXs they examined utilized glucose, not glutamine, to fuel the TCA cycle. In contrast to the findings in these two studies, using hyperpolarized [1-13C] glutamine magnetic resonance imaging, Salamanca-Cardona and colleagues reported that glutamine, but not glucose, enters the TCA cycle to generate 2-hydroxyglutarate \textit{in vivo} in patient-derived chondrosarcoma with IDH1 or IDH2 mutation. Of interest, a recent study indicated that glutamine is the predominant carbon source for the TCA cycle for pancreas, intestine and spleen, whereas glucose or lactate is the major carbon source for the TCA cycle in brain, lung, and other tissues. The seemingly discordant results in the literature for glutamine utilization by cancers may reflect differences among tissue/cell context, genetic and epigenetic differences in different tumor types, and potentially various other factors and mechanisms. Consistently, we did not detect any [13C6]-glucose in the CRC xenograft tumors, precluding us from calculating the percentages of TCA cycle metabolites derived from glucose.

Our [13C5]-glutamine tracing data in tissue culture and subcutaneous xenograft tumors show that isogenic PIK3CA-mutant CRCs utilize more anaplerotic glutamine than PIK3CA-WT counterparts. In the orthotopic models, the enrichments of TCA cycle intermediates are higher in PIK3CA-mutant than in the WT tumors, but they are not statistically significant. This discrepancy may due to the small sample size and experimental variabilities of the orthotopic models. In the subcutaneous xenograft models, isogenic PIK3CA WT and mutant cells are
implanted pair-wise into the same mouse, whereas in the othotopic models each mouse bears either a PIK3CA WT or a mutant tumor. Thus, the experimental conditions in the subcutaneous xenograft models are better controlled than in the orthotopic models. We believe that the data obtained in the subcutaneous models reflect the intrinsic difference of glutamine metabolism between PIK3CA WT and mutant tumors, that is, PIK3CA mutant tumors are more dependent on anaplerotic glutamine. However, we could not completely rule out the possibility that the difference in glutamine anaplerosis between PIK3CA mutant and WT tumors is a consequence of different tumor growth rate. Nonetheless, we found that, as with AOA, CB-839 preferentially inhibits xenograft tumor growth of PIK3CA mutant, but not WT, CRC xenograft tumor growth. Moreover, the combination of CB-839 and 5-FU induced tumor regression in three different PIK3CA mutant CRC xenograft models. These exciting results prompted to conduct a phase I/II clinical trial of combinational of CB-839 with capecitabine, an oral prodrug of 5-FU. The phase I trial demonstrated that the drug combination is well tolerated at biologically-active doses. Consistent with the preclinical data, an exploratory analysis of time on treatment and progression free survival suggests that PIK3CA-mutant CRC patients may derive greater benefit from this treatment strategy as compared to PIK3CA WT CRC patients.

Although our studies focus on CRCs, in vivo glutamine dependency may be a general phenomenon for various tumor types, as recent studies demonstrate that a variety of tumor types including breast, pancreatic, kidney cancers as well as acute myeloid leukemia are sensitive to a glutaminase inhibitor, CB-839, in vivo. Clinical trials...
trials of combination of CB-839 with various therapeutic agents are ongoing in patients with renal cell carcinomas (RCC), melanoma, or non-small cell lung cancer (https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/glutaminase-inhibitor-cb-839). Interestingly, Combinations of CB-839 with cabozantinib, everolimus have shown promising results in a phase I clinical trial in RCC patients. Further studies should help to better define factors and mechanisms accounting for glutamine dependency in vivo in different cancer types and the ramifications arising from such a dependency for improving treatment outcomes in cancer patients.

**Figure 5.** More $^{13}$C$_5$-glutamine enters the TCA cycle in PIK3CA mutant tumors than adjacent normal tissue in genetically engineered mice. CDX2P-CreERT$^2$ Apc$^{flox/+}$ Kras$^{LSL-G12D/+}$ Pik3ca$^{LSL-E545K/+}$ mice were treated with tamoxifen to conditionally express the Kras and Pik3ca oncogenes and to delete Apc. Two moths post-treatment, mice were infused with $^{13}$C$_5$-glutamine. Representative image of H & E staining of a colon tumor is shown in (A). Arrow indicates a tumor invaded to the muscle layer. The M5 enrichment of glutamine and the M4 enrichments of metabolites directly derived from M5 glutamine are shown in (B). Percentages of total $^{13}$C-labeled metabolites normalized to total $^{13}$C-labeled glutamine in tumors are plotted in (C). *p < 0.05, **p < 0.01, ***p < 0.001; the Student’s t test.
Materials and Methods

Cell culture. HCT116 CRC cell lines were obtained from ATCC (catalog # CCL-247). The isogenic HCT116 PIK3CA WT and mutant only cell lines were kindly gifts from Dr. Bert Vogelstein at John Hopkins University. These cell lines were cultured in McCoy’s 5A medium containing 10% fetal bovine serum as described previously27. The tissue cultures were routinely checked to ensure free of mycoplasma contamination. The cell lines were described by the Genetica DNA Laboratories using STR profiling.

Animal models. Animal experiments were approved by the Case Western Reserve University Animal Care and Use Committee. All experiments were performed in accordance with relevant guidelines and regulations.

Subcutaneous xenograft. As described in28, 3 million cells were injected subcutaneously into the flanks of 6 to 8-week-old female athymic nude mice.

Orthotopic xenograft. Eight-week-old female nude mice were anesthetized by intraperitoneal injection of ketamine (104 mg/kg) and xylazine (9 mg/kg) and disinfected with iodine/alcohol prep pads. A laparotomy incision of approximately 1.0 cm was made in the skin just to the right of the abdomen midline. The cecum was pulled out of the abdomen and a piece of subcutaneous xenograft tumor (~1 mm³) was attached to the serosa of cecum using 6–0 silk sutures. The cecum was then put back in the abdominal cavity. The muscle layer and abdominal wall were closed with 4–0 Vicryl plus antibacterial violet sutures.

Genetically engineered mice. Apcflox/flox mice29, Pik3caSL-E545K/+ mice30, and KrasLSL-G12D/+ mice31 have been previously described. CDX2P-CreERT2 transgenic mice32 were first intercrossed with Apcflox/flox mice and Pik3caSL-E545K/+ mice to generate the CDX2P-CreERT2 Apcflox/flox Pik3caSL-E545K/+ mice. These mice were then bred to KrasLSL-G12D/+ mice to produce the CDX2P-CreERT2 Apcflox/cre KrasLSL-G12D/+ Pik3caSL-E545K/+ mice. For Cre-mediated deletion of the Apc floxed allele and the lox-STOP-lox cassette (LSL) in KrasLSL-G12D and Pik3caSL-E545K mutant alleles, the mice were injected intraperitoneally with tamoxifen (100 mg/kg body weight; Sigma-Aldrich, St Louis, MO) once daily for 2 days. Two months post tamoxifen administration, the mice were infused with [13C]glutamine to check the glutamine usage.

Mouse infusion. Surgical procedures were similar to those established by the Mouse Metabolic Phenotyping Consortium33. Briefly, mice were anesthetized and a 2 cm skin incision was made on the right side of the neck. Blunt forceps were used to isolate a 5 mm section of the jugular vein and 4–0 silk suture was tied on both proximal and distal ends of the vessel. RenaSil Silicone Rubber Tubing (0.025 ″ ID) was inserted into the vein.

Metabolite assays. Frozen tissue was homogenized with metabolite extraction buffer (90% methanol and 10% PBS, pre-chilled in −80 °C). For 100 mg tissue, 1 ml of buffer was applied. 5 µM of heptadecanoic acid, 2.5 µM of [3,3,4,5,5,5-2H6]4-hydroxyoctanoic acid and 2.5 µM of [2,2,3,3,4,4,5,5,6,6,7,7,7-2H13]heptadecanoic acid were added into the extraction buffer as internal standards. After centrifuging at 14,000 rpm for 15 min at 4 °C, the supernatant was collected and dried with nitrogen gas. TBDMS (MTBSTFA, REGIS Technologies):Acetonitrile (Agilent Technologies) for analysis. For the analysis of the fraction of C13 labeled metabolites, the total pool of C13 labeled metabolites was used. The formula of (1 + M1%)/(n) was applied. For glucose analysis with GC-MS, samples were processed with extraction buffer (90% methanol and 10% PBS, pre-chilled in −80 °C). The supernatant was collected and dried with nitrogen gas. To the dried residue, hydroxyalmine hydrochloride (2.1 mg) in 100 µl of pyridine was added and the mixture heated at 90 °C for 30 min, then 75 µl of acetic anhydride was added and heated for an additional hour. The reaction mixture was cooled, partitioned between water and methylene chloride layer. The methylene chloride layer was then transferred to a vial, dried in a stream of air and reconstituted with 50 µl of ethyl acetate.

H&E staining. H & E staining was performed as described34. Briefly, formalin-fixed, paraffin-embedded tissue sections (5 µm) were pre-warmed in a 60 °C incubator for 1 h 15 min, then were deparaffinized in xylene and rehydrated in ethanol gradient. Sections were stained with hematoxylin and eosin (H&E).

Statistical analysis. GraphPad Prism software was used to create the graphs. Data are plotted as mean ± SEM. We applied the t test to compare the means between two groups, assuming unequal variances.

Data availability

All data generated or analysed during this study are included in this published article (and its Supplementary Information Files).

Received: 24 July 2019; Accepted: 28 November 2019;
Published online: 16 December 2019
27. Hao, Y.
31. Jackson, E. L.
29. Shibata, H.

5. Jiang, B. Aerobic glycolysis and high level of lactate in cancer metabolism and microenvironment. Cell metabolism 13, 1302–1315, https://doi.org/10.1016/j.cmet.2016.01.001 (2012).
6. Samuels, Y. et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer cell 7, 561–573 (2005).

3. Zhang, J., Pavlova, N. N. & Thompson, C. B. Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. Nature reviews. Cancer 13, 148–161, https://doi.org/10.1038/nrc3459 (2013).

2. Altman, B. J., Stine, Z. E. & Dang, C. V. From Krebs to clinic: glutamine metabolism to cancer therapy. Cancer cell biology 15, 827–837, https://doi.org/10.1016/j.cmet.2012.05.001 (2012).

6. Lv, X. et al. Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. The American journal of pathology 183, 2562–2567, https://doi.org/10.1016/j.ajpath.2013.04.013 (2013).

19. Wang, Z. J. & Hao, Y. Abstract C115: Targeting glutamine metabolism in colorectal cancers with PIK3CA mutations. Molecular cancer 6, 11971, https://doi.org/10.1038/ncomms11971 (2016).

20. Eads, J. R. et al. Phase 1 clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors. The American journal of pathology 183, 2562–2567, https://doi.org/10.1016/j.ajpath.2013.04.013 (2013).

14. Marin-Valencia, I. et al. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). JCO.2016.34.15_suppl.4568 (2016).

23. Meric-Bernstam, F. et al. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). Journal of Clinical Oncology 34, 4568–4568, https://doi.org/10.1200/JCO.2016.34.15_suppl.4568 (2016).

24. Gregory, M. A. et al. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia. Experimental hematology, https://doi.org/10.1016/j.exphem.2017.09.007 (2017).

15. Meric-Bernstam, F. et al. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). Journal of Clinical Oncology 34, 4568–4568, https://doi.org/10.1200/JCO.2016.34.15_suppl.4568 (2016).

25. Meric-Bernstam, F. et al. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). JCO.2016.34.15_suppl.4568 (2016).

26. Tannir, N. M. et al. CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma. TP54601–TP54601, https://doi.org/10.1200/JCO.2018.36.15_suppl.TP54601 (2018).

27. Hao, Y. et al. Gain of interaction with IRS1 by p110alpha-helical domain mutants is crucial for their oncogenic functions. Cancer cell 23, 583–593, https://doi.org/10.1016/j.ccr.2013.02.031 (2013).

28. Zhao, Y. et al. Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proceedings of the National Academy of Sciences of the United States of America 107, 2592–2597, 01914884107, https://doi.org/10.1073/pnas.1611061113 (2016).

29. Meric-Bernstam, F. et al. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). Journal of Clinical Oncology 34, 4568–4568, https://doi.org/10.1200/JCO.2016.34.15_suppl.4568 (2016).

30. Robinson, G. et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488, 43–48, https://doi.org/10.1038/nature11213 (2012).

31. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes & development 15, 3243–3248, https://doi.org/10.1101/gad.943001 (2001).

32. Feng, Y. et al. Sox9 induction, ectopic Paneth cells, and mitotic spindle axis defects in mouse colon adenomatous epithelium arising from conditional biallelic Apc inactivation. The American journal of pathology 183, 493–503, https://doi.org/10.1016/j.ajpath.2013.04.013 (2013).

33. Ayala, J. E. et al. Hyperinsulinemic-euglycemic clamps in conscious, unrestrained mice. Journal of visualized experiments: JoVE, https://doi.org/10.3791/3188 (2011).

34. Zhao, Y. et al. Regulation of paxillin-p130–PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis. Oncotarget, https://doi.org/10.18632/oncotarget.10654 (2016).
Author contributions
Funding Acquisition, Z.W.; Conceptualization: Z.W., Y.H., Y.Z., H.B.; Experimental design: Z.W., H.B., Y.Z., R.A.C., M.P. and C.C.; Experiment implementation: Y.Z., Y.H., X.Z., Y.F., L.W. and M.P.; Providing critical reagents: Y.F., E.F. and S.M.; Manuscript writing: Z.W., H.B., Y.H., Y.Z., R.A.C. and E.F.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-55718-2.

Correspondence and requests for materials should be addressed to Y.H. or Z.W.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019